We use technology to improve diagnostic and treatment accuracy for patients. We develop state of the art solutions to improve clinical outcome, and hence improve quality of life.
Biobot Surgical Pte Ltd aims to be a global technology leader in minimally-invasive robotic healthcare solutions.
Biobot Surgical Pte Ltd was incorporated in 2007 in Singapore, and became a member of ZIG Venture since 2011.
To ensure success, a team of talents has been put together in the areas of robotic design and technology, medical image processing, software development and clinical application.
To date, the iSR’obot Mona Lisa has obtained key regulatory approvals, including Europe (CE mark), U.S.A (US FDA), Australia (TGA) and Singapore (HSA) and is being used in some of the most prestigious hospitals around the world.
Striving to become the gold standard in diagnosis and prognosis of prostate cancer, the Mona Lisa’s development has been a process of evolution and is the latest in our state of the art new generation designs.
Since March 2021, ZIG Ventures has been appointed a partner under the Enterprise Singapore Innovation and Enterprise Fellowship (IFP) Programme. There is an opening for ZIG Innovation Fellowship Program.
ZIG Ventures is a venture investment and commercialization company that focuses on investing into healthcare biomedical technologies companies and proactively develops these companies by working side by side with the founders, building key capabilities and driving commercialization through its global key opinion and distributorship networks.
Biobot Surgical is a member of ZIG Ventures.
Click on this post to find out more about the program!
We are proud to share our debut showcase in Myanmar at the 4th Myanmar Nephro-Urology Society Conference held over the weekend on 12-13 Oct 2019.
We are honoured to be exhibiting again this year at the Asia Pacific MedTech Forum 2019 at Booth No. 3. This year’s theme is “Connecting Leaders, Connecting Care”.
Thank you everyone who visited our booth!
“Robotic prostate biopsy and needle localization are technological developments that have the potential to positively influence the diagnosis and management of prostate cancer. All of that enables more precise and accurate localization of targets”
Dr. dr. Irfan Wahyudi, Sp.U (K), Head of the Urology Department of RSCM-FKUI, in Jakarta
(Article in bahasa Indonesia; quote based on google translation )
Thank you for visiting us at Asia-Pacific Prostate Cancer Conference 2019!